Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition
Background: Inositol was previously classified as a vitamin, but it is not one as it is produced by the body. It plays a role as a second messenger of insulin in several insulin-dependent processes, including polycystic ovarian syndrome (PCOS) and metabolic syndrome. Objective: This study aims to de...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Medical Journal of Babylon |
| Subjects: | |
| Online Access: | https://doi.org/10.4103/MJBL.MJBL_1026_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841525570724167680 |
|---|---|
| author | Zuhair Assi Hussein Maysaa Jalal Majeed Lubna Amer Al-Anbari |
| author_facet | Zuhair Assi Hussein Maysaa Jalal Majeed Lubna Amer Al-Anbari |
| author_sort | Zuhair Assi Hussein |
| collection | DOAJ |
| description | Background: Inositol was previously classified as a vitamin, but it is not one as it is produced by the body. It plays a role as a second messenger of insulin in several insulin-dependent processes, including polycystic ovarian syndrome (PCOS) and metabolic syndrome. Objective: This study aims to determine the impact of myo+ D-chiro inositol treatment on gut hormones insulin-like peptide 5 (ILP5) and phosphodiesterase 9 (PDE9) inhibitors, as well as determine if it improves the metabolic profile and the state of PCOS. Materials and Methods: The research conducted by the University of Baghdad’s College of Medicine was authorized by the ethics committee. In the study, 50 obese women without PCOS, and 50 obese women with PCOS were enrolled, and they were then treated with 2000 mg of myo-inositol (MI) and 50 mg of D-chiro inositol (DCI) in a 40:1 ratio for 3 months while having their vital signs and laboratory tests checked both before and after the treatment. We examined fasting glucose, insulin, ILP5, PDE9 inhibitor, free testosterone, dehydroepiandrosterone, the homeostatic model assessment index, and pretreatment and posttreatment. From February 2022 to the end of August 2022, participants in the study visited the Infertility Unit at the Higher Institute for Infertility Diagnosis and Assisted Reproductive Technologies at Al-Nahrain University in Baghdad, Baghdad, Iraq. Participants in this research completed questionnaires to indicate their consent for the study to record information on women. Results: The results revealed that after administering the treatment to polycystic ovary patients, a significant decrease in their weight and an improvement in insulin resistance markers were observed, as well as a decrease in the levels of ILP5 (171.53 ± 22.55 vs. 83.60 ± 18.94), and an increase in the levels of phosphodiesterase9 enzyme (7.17 ± 1.58 ng/mL vs. 8.16 ± 1.37 ng/mL). Conclusion: This study concludes that MI–DCI could be proposed as a potential therapeutic approach for the treatment of women with polycystic ovaries, showing a positive effect on correcting PCOS symptoms and infertility. |
| format | Article |
| id | doaj-art-bfac46e20ed6434488a4feba355b7fae |
| institution | Kabale University |
| issn | 1812-156X 2312-6760 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Medical Journal of Babylon |
| spelling | doaj-art-bfac46e20ed6434488a4feba355b7fae2025-01-17T10:54:56ZengWolters Kluwer Medknow PublicationsMedical Journal of Babylon1812-156X2312-67602024-12-0121478578910.4103/MJBL.MJBL_1026_23Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome ConditionZuhair Assi HusseinMaysaa Jalal MajeedLubna Amer Al-AnbariBackground: Inositol was previously classified as a vitamin, but it is not one as it is produced by the body. It plays a role as a second messenger of insulin in several insulin-dependent processes, including polycystic ovarian syndrome (PCOS) and metabolic syndrome. Objective: This study aims to determine the impact of myo+ D-chiro inositol treatment on gut hormones insulin-like peptide 5 (ILP5) and phosphodiesterase 9 (PDE9) inhibitors, as well as determine if it improves the metabolic profile and the state of PCOS. Materials and Methods: The research conducted by the University of Baghdad’s College of Medicine was authorized by the ethics committee. In the study, 50 obese women without PCOS, and 50 obese women with PCOS were enrolled, and they were then treated with 2000 mg of myo-inositol (MI) and 50 mg of D-chiro inositol (DCI) in a 40:1 ratio for 3 months while having their vital signs and laboratory tests checked both before and after the treatment. We examined fasting glucose, insulin, ILP5, PDE9 inhibitor, free testosterone, dehydroepiandrosterone, the homeostatic model assessment index, and pretreatment and posttreatment. From February 2022 to the end of August 2022, participants in the study visited the Infertility Unit at the Higher Institute for Infertility Diagnosis and Assisted Reproductive Technologies at Al-Nahrain University in Baghdad, Baghdad, Iraq. Participants in this research completed questionnaires to indicate their consent for the study to record information on women. Results: The results revealed that after administering the treatment to polycystic ovary patients, a significant decrease in their weight and an improvement in insulin resistance markers were observed, as well as a decrease in the levels of ILP5 (171.53 ± 22.55 vs. 83.60 ± 18.94), and an increase in the levels of phosphodiesterase9 enzyme (7.17 ± 1.58 ng/mL vs. 8.16 ± 1.37 ng/mL). Conclusion: This study concludes that MI–DCI could be proposed as a potential therapeutic approach for the treatment of women with polycystic ovaries, showing a positive effect on correcting PCOS symptoms and infertility.https://doi.org/10.4103/MJBL.MJBL_1026_23chirod-inositol-insulin-like peptide 5myo-pcosphosphodiesterase 9 inhibitors |
| spellingShingle | Zuhair Assi Hussein Maysaa Jalal Majeed Lubna Amer Al-Anbari Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition Medical Journal of Babylon chiro d-inositol-insulin-like peptide 5 myo-pcos phosphodiesterase 9 inhibitors |
| title | Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition |
| title_full | Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition |
| title_fullStr | Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition |
| title_full_unstemmed | Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition |
| title_short | Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition |
| title_sort | impact of myo inositol chiro inositol combination on the improvement of polycystic ovary syndrome condition |
| topic | chiro d-inositol-insulin-like peptide 5 myo-pcos phosphodiesterase 9 inhibitors |
| url | https://doi.org/10.4103/MJBL.MJBL_1026_23 |
| work_keys_str_mv | AT zuhairassihussein impactofmyoinositolchiroinositolcombinationontheimprovementofpolycysticovarysyndromecondition AT maysaajalalmajeed impactofmyoinositolchiroinositolcombinationontheimprovementofpolycysticovarysyndromecondition AT lubnaameralanbari impactofmyoinositolchiroinositolcombinationontheimprovementofpolycysticovarysyndromecondition |